Equities Research Analysts’ Updated EPS Estimates for January 8th (ABSI, ACCD, ADBE, AIG, AMD, ARIS, BECN, BLDR, CMPX, DAY)

Equities Research Analysts’ updated eps estimates for Wednesday, January 8th:

Absci (NASDAQ:ABSI) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $7.00 price target on the stock.

Accolade (NASDAQ:ACCD) had its market perform rating reissued by analysts at Leerink Partners.

Adobe (NASDAQ:ADBE) had its hold rating reissued by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $475.00 price target on the stock, down from their previous price target of $600.00.

American International Group (NYSE:AIG) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They currently have a $79.00 target price on the stock, down from their previous target price of $83.00.

Advanced Micro Devices (NASDAQ:AMD) had its reduce rating reiterated by analysts at HSBC Holdings plc. They currently have a $110.00 target price on the stock, down from their previous target price of $200.00.

Aris Water Solutions (NYSE:ARIS) had its neutral rating reissued by analysts at Citigroup Inc.. Citigroup Inc. currently has a $26.00 price target on the stock, up from their previous price target of $18.00.

Beacon Roofing Supply (NASDAQ:BECN) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $115.00 target price on the stock.

Builders FirstSource (NYSE:BLDR) had its buy rating reissued by analysts at Stifel Nicolaus. They currently have a $175.00 target price on the stock.

Compass Therapeutics (NASDAQ:CMPX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $10.00 target price on the stock.

Compass Therapeutics (NASDAQ:CMPX) had its buy rating reissued by analysts at D. Boral Capital. The firm currently has a $32.00 price target on the stock.

Dayforce (NYSE:DAY) had its hold rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $80.00 target price on the stock, down from their previous target price of $85.00.

Ferguson (NASDAQ:FERG) had its neutral rating reiterated by analysts at UBS Group AG. They currently have a $193.00 target price on the stock, down from their previous target price of $230.00.

Federated Hermes (NYSE:FHI) had its hold rating reissued by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $43.00 price target on the stock, down from their previous price target of $45.00.

Fidelis Insurance (NYSE:FIHL) had its sell rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. The Goldman Sachs Group, Inc. currently has a $16.00 target price on the stock, down from their previous target price of $21.00.

Flutter Entertainment (NYSE:FLUT) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $300.00 price target on the stock.

Getty Images (NYSE:GETY) had its neutral rating reissued by analysts at Macquarie. The firm currently has a $3.75 price target on the stock.

Genmab A/S (NASDAQ:GMAB) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $50.00 target price on the stock.

Holley (NYSE:HLLY) had its outperform rating reissued by analysts at Telsey Advisory Group. They currently have a $4.50 price target on the stock.

Immuneering (NASDAQ:IMRX) had its buy rating reiterated by analysts at Chardan Capital. Chardan Capital currently has a $13.00 target price on the stock.

JELD-WEN (NYSE:JELD) had its neutral rating reaffirmed by analysts at UBS Group AG. They currently have a $9.00 price target on the stock, down from their previous price target of $15.00.

Kura Sushi USA (NASDAQ:KRUS) had its outperform rating reiterated by analysts at William Blair.

Merck & Co., Inc. (NYSE:MRK) had its hold rating reissued by analysts at Truist Financial Co.. Truist Financial Co. currently has a $110.00 price target on the stock, down from their previous price target of $130.00.

Inari Medical (NASDAQ:NARI) had its neutral rating reiterated by analysts at BTIG Research.

NVIDIA (NASDAQ:NVDA) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $220.00 target price on the stock.

OLO (NYSE:OLO) had its neutral rating reissued by analysts at Piper Sandler. They currently have a $8.00 target price on the stock.

OPKO Health (NASDAQ:OPK) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $3.00 price target on the stock.

OptimizeRx (NASDAQ:OPRX) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $6.00 target price on the stock, down from their previous target price of $7.00.

Palo Alto Networks (NASDAQ:PANW) had its hold rating reissued by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a $190.00 price target on the stock, down from their previous price target of $207.00.

BiomX (NYSEAMERICAN:PHGE) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $2.00 price target on the stock.

Personalis (NASDAQ:PSNL) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $11.00 price target on the stock.

Personalis (NASDAQ:PSNL) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $7.25 target price on the stock.

Paycor HCM (NASDAQ:PYCR) had its market perform rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a $22.50 target price on the stock, down from their previous target price of $24.00.

AVITA Medical (NASDAQ:RCEL) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $25.00 price target on the stock.

SolarEdge Technologies (NASDAQ:SEDG) had its sell rating reissued by analysts at Citigroup Inc.. The firm currently has a $9.00 price target on the stock, down from their previous price target of $12.00.

Simulations Plus (NASDAQ:SLP) had its outperform rating reiterated by analysts at William Blair.

Sensei Biotherapeutics (NASDAQ:SNSE) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $4.00 target price on the stock.

Stoke Therapeutics (NASDAQ:STOK) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $22.00 price target on the stock.

Stoke Therapeutics (NASDAQ:STOK) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $35.00 price target on the stock.

Trevi Therapeutics (NASDAQ:TRVI) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $21.00 price target on the stock.

TETRA Technologies (NYSE:TTI) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $5.50 price target on the stock.

Unicycive Therapeutics (NASDAQ:UNCY) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $4.00 target price on the stock.

Viking Therapeutics (NASDAQ:VKTX) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $102.00 target price on the stock.

VolitionRx (NYSE:VNRX) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $5.00 target price on the stock.

Verona Pharma (NASDAQ:VRNA) had its buy rating reissued by analysts at Truist Financial Co.. Truist Financial Co. currently has a $57.00 target price on the stock, up from their previous target price of $44.00.